Inflammatory markers in patients with rheumatoid arthritis

Allergologia et Immunopathologia

Volumn 43, Issue 1, 2015, Pages 81-87

  Shrivastava, A K ^a   Singh, H V ^b   Raizada, A ^c   Singh, S K ^d   Pandey, A ^e   Singh, N ^d   Yadav, D S ^c   Sharma, H ^b  

^a Sudha Rustagi College of Dental Sciences and Research   (India)

^b HINDU RAO HOSPITAL   (India)

^c Department of Pathology and Laboratory Medicine Medanta The Medicity ^*  (India)

^d G R MEDICAL COLLEGE   (India)

^e Narsinhbhai Patel Dental College and Hospital   (India)

Author keywords

Hs CRP; Inflammation; Interleukin 10; Interleukin 6; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DAS28; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; TERTIARY CARE CENTER; ARTHRITIS, RHEUMATOID; BLOOD; DISEASE COURSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHOTOMETRY; SEVERITY OF ILLNESS INDEX;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; SEVERITY OF ILLNESS INDEX;

EID: 84921543224     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2013.11.003     Document Type: Article

References (33)

1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
2. Cassim B., Mody G., Bhoola K. Kallikrein cascades and cytokines in inflamed joints. Pharmacol Ther 2002, 94:1-34.
3. Goldbach-Mansky R., Lipsky P.E. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 2003, 54:197-216.
4. Hanna F.S., Bell R.J., Cicuttini F.M., Davison S.L., Wluka A.E., Davis S.R. High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life. Arthritis Res Ther 2008, 10:R27.
5. Shrivastava A.K., Pandey A. Inflammation and rheumatoid arthritis. J Physiol Biochem 2013, 69:335-347.
6. Nielen M.M., van Schaardenburg D., Reesink H.W., Twisk J.W., van de Stadt R.J., van der Horst-Bruinsma I.E., et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004, 50:2423-2427.
7. Fox D.A. Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor. Arch Intern Med 2000, 160:437-444.
8. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442.
9. Jenkins J.K., Hardy K.J., McMurray R.W. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci 2002, 323:171-180.
10. Rahman E.M.A., Ezzat H., Mohsen M.M.A., Yosef K. Interleukin-10 Interleukin-16 and Interferon-γ in serum of patients with rheumatoid arthritis and correlation with disease activity. Egypt J Hosp Med 2005, 20:46-57.
11. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
12. Edwards C.K., Green J.S., Volk H.D., Schiff M., Kotzin B.L., Mitsuya H., et al. Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. Front Immunol 2012, 3:366.
13. Plant M.J., Williams A.L., O'Sullivan M.M., Lewis P.A., Coles E.C., Jessop J.D. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:1473-1477.
14. Singh H.V., Shrivastava A.K., Raizada A., Singh S., Pandey A., Singh N., et al. Atherogenic lipid profile and high sensitive C-reactive protein in patients with rheumatoid arthritis. Clin Biochem 2013, 46:1007-1012.
15. Masi A.T., Aldag J.C., Sipes J. Do elevated levels of serum C-reactive protein predict rheumatoid arthritis in men: correlations with pre-RA status and baseline positive rheumatoid factors. J Rheumatol 2001, 28:2359-2361.
16. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
17. Murakami M., Nishimoto N. Inflammatory cytokines in rheumatoid arthritis. Clin Calcium 2012, 22:1737-1746.
18. Antoniv T.T., Ivashkiv L.B. Dysregulation of interleukin-10 dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum 2006, 54:2711-2721.
19. Mittal G.A., Joshi V.R. IL-10 in early rheumatoid arthritis. Indian Rheumatol Assoc 2002, 10:59-60.
20. William St Clair E. Interleukin-10 treatment for rheumatoid arthritis. Ann Rheum Dis 1999, 58:99-102.
21. Badolato R., Oppenheim J.J. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996, 26:526-538.
22. Hovdenes J., Kvien T.K., Hovdenes A.B. IL-6 in synovial fluids, plasma and supernatants from cultuted cells or patients with rheumatoid arthritis and other inflammatory arthritides. Scand J Rheumatol 1990, 19:177-182.
23. Aletaha D., Smolen J., Ward M.M. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006, 54:2784-2792.
24. Hirata S., Dirven L., Shen Y., Centola M., Cavet G., Lems W.F., et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013, 52:1202-1207.
25. Wells G., Becker J.C., Teng J., Dougados M., Schiff M., Smolen J., et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68:954-960.
26. Dessein P.H., Joffe B.I., Stanwix A.E. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 2004, 31:1095-1097.
27. Skogh T., Gustafsson D., Kjellberg M., Husberg M. Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate. Ann Rheum Dis 2003, 62:681-682.
28. Emery P., Gabay C., Kraan M., Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007, 27:793-806.
29. Machold K.P., Stamm T.A., Nell V.P., Pflugbeil S., Aletaha D., Steiner G., et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007, 46:342-349.
30. Choy E.H.S., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl J Med 2001, 344:907-916.
31. Milman N., Karsh J., Booth R.A. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem 2010, 43:1309-1314.
32. Blake G.J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ Res 2001, 89:763-771.
33. Shmerling R.H. Diagnostic tests for rheumatic disease: clinical utility revisited. South Med J 2005, 98:704-711.